New Drug Formulation Shows Potential to Treat Candida Infections
Because oral Candida albicans infections are often painful, researchers at the University of Bristol in the United Kingdom have developed a new drug formulation to improve the efficiency and reduce the side effects of existing antifungal drugs.
Although approved to treat Candida infections, the antibiotic fluconazole is ineffective against Candida biofilms. In an effort to improve its action in these cases, researchers used a chemical signaling molecule secreted by Pseudomonas aeruginosa to enhance fluconazole’s effectiveness. Published in the International Journal of Pharmaceutics, the study notes that codelivering fluconazole with a P. aeruginosa quorum-sensing molecule, N-3-oxo-dodecanoyl-L-homoserine lactone, in a liposomal formulation suppressed C. albicans biofilms.
From Decisions in Dentistry. October 2020;6(9):6.
